Wallin et al. described increased phosphorylation of AKT upon doxorubicin treatment in breast and ovarian cancer cell lines, inducing a synergistic antitumor effect when combining doxorubicin with an agent targeting the PI3K/AKT pathway [26]. This evidence concerns the gene AKT1 and ovarian cancer.